Finanzen von Ensysce Biosciences Inc (ENSC)ENSCEnsysce Biosciences Inc

Evaluating the bottom line, Ensysce Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -221.28%, while the net margin is -220.81%. These profitability ratios, combined with a Return on Equity (ROE) of -968.33%, provide a clear picture of how effectively ENSC converts its operational activities into shareholder value.

In the context of the broader market, ENSC competes directly with industry leaders such as FBLG and XCUR. With a market capitalization of $6.57M, it holds a significant position in the sector. When comparing efficiency, ENSC's gross margin of 100.00% stands against FBLG's N/A and XCUR's N/A. Such benchmarking helps identify whether Ensysce Biosciences Inc is trading at a premium or discount relative to its financial performance.

Ensysce has shown erratic revenue growth, with Q2 2026 revenue at $1,164,315, but it has also reported consistent net losses, including a net income of -$2,570,709 for Q2 2026. The gross margin remains high at 100%, but this is offset by the lack of profitability and increasing operational losses.